NASDAQ:MRKR

Marker Therapeutics - MRKR Stock Forecast, Price & News

$0.30

0.00 (0.00%)

(As of 11/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.29
▼
$0.32
50-Day Range: $0.29
▼
$0.46
52-Week Range: $0.25
▼
$1.26

Volume: 117,663 shs
Average Volume: 233,071 shs
Market Capitalization: $25.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.25

Marker Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 316.5% Upside
$1.25 Price Target
Short Interest: Healthy
1.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.62
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.46) to ($0.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

215th out of 1,038 stocks

Pharmaceutical Preparations Industry

88th out of 510 stocks

3.0

Analyst's Opinion

Consensus Rating
Marker Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.25, Marker Therapeutics has a forecasted upside of 316.5% from its current price of $0.30.
Amount of Analyst Coverage
Marker Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.69% of the float of Marker Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Marker Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Marker Therapeutics has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Marker Therapeutics does not currently pay a dividend.
Dividend Growth
Marker Therapeutics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Marker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Marker Therapeutics is -0.75.

2.6

News and Social Media Coverage

News Sentiment
Marker Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 1 article on an average week.
Search Interest
8 people have searched for MRKR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.20% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 26.62% of the stock of Marker Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Marker Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Marker Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Marker Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Marker Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Marker Therapeutics (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

November 26, 2022 | marketwatch.com

Marker Pens Market Analysis Report 2023 Along with Statistics Figures, Forecasts till 2028

November 22, 2022 | finance.yahoo.com

Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

November 11, 2022 | marketwatch.com

Fiber Laser Marker Market 2022 Share Booming Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2027 | 138 Pages Report

November 10, 2022 | finance.yahoo.com

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

November 10, 2022 | finance.yahoo.com

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

November 10, 2022 | marketwatch.com

Global CO2 Laser Marker Market Size and Overview Report 2022 by Recent Developments, Industrial Trends, Top Vendors and Forecast to 2028

November 9, 2022 | marketwatch.com

Cardiac Marker Testing Market 2022 - Future Developments, Key Vendors, Regional Analysis, and Industry Scope by 2028

November 9, 2022 | marketwatch.com

Chronic Phase Marker Market 2022 : Report Offers Key Futuristic Top Trends And Competitive Landscape By 2028

November 7, 2022 | msn.com

New DAR Patriot's Marker at Old Eagle School marks America's 250th

November 2, 2022 | marketwatch.com

Gas Laser Marker Market to Grow Significantly by Leading Players 2022 to 2028 | 123 Pages Report

November 1, 2022 | benzinga.com

The Neurobiology of Pain Processing and Suicide: A Potential Marker for Suicide Risk - A Free Webinar from the Brain & Behavior Research Foundation

October 20, 2022 | marketwatch.com

Paint Marker Market 2022 to Eyewitness Massive Growth by 2028

October 18, 2022 | marketwatch.com

Bone Marker Market Share, Size Global Growth Prospects, Growth, Trends, Industry Analysis, Key Players and Forecast to 2028

October 14, 2022 | marketwatch.com

Wire Marker Card Market 2022 : Projections and Regional Outlook, Key Players, Analysis, Size, Share, Growth, Trends and Forecast to 2029

October 12, 2022 | finanznachrichten.de

Cardiac Marker Testing Market worth $7.7 billion by 2027 - Exclusive Report by MarketsandMarkets

September 13, 2022 | bbc.com

Queen Elizabeth II: Swan Marker David Barber recalls monarch's interest in birds

September 13, 2022 | finance.yahoo.com

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

September 9, 2022 | msn.com

Clues at Marker 15? Debris, damage indicate Keys boat may have veered outside channel

September 8, 2022 | finance.yahoo.com

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

September 2, 2022 | msn.com

How to get the Error Marker in Find the Markers – Roblox

September 1, 2022 | msn.com

How to get the … Marker in Find the Markers – Roblox

August 30, 2022 | msn.com

How to get the Runner Marker in Roblox Find the Markers

August 29, 2022 | msn.com

How to get the Serenity Marker in Roblox Find the Markers

August 26, 2022 | msn.com

How to get the Killbrick Marker in Roblox Find the Markers

August 18, 2022 | nasdaq.com

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Company Calendar

Last Earnings: 11/10/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/16/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRKR
CUSIP: N/A
CIK: 1094038
Web: www.markertherapeutics.com
Phone: (713) 400-6400
Fax: N/A
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.25
High Stock Price Forecast: $1.50
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +316.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,880,000.00
Net Margins: -515.88%
Pretax Margin: -515.89%
Return on Equity: -110.00%
Return on Assets: -66.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.99
Quick Ratio: 1.99

Sales & Book Value

Annual Sales: $1.24 million
Price / Sales: 20.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.27 per share
Price / Book: 1.11

Miscellaneous

Outstanding Shares: 83,600,000
Free Float: 60,860,000
Market Cap: $25.09 million
Optionable: Optionable
Beta: 1.12

Key Executives

Mr. Peter L. Hoang MBA (Age 50)
Pres, CEO & Director
Comp: $617.13k

Dr. Mythili Koneru M.D. (Age 44)
Ph.D., Chief Medical Officer
Comp: $550.14k

Dr. Juan F. Vera M.D. (Age 42)
Co-Founder, COO, Chief Scientific Officer & Director

Mr. Michael J. Loiacono (Age 56)
Chief Accounting Officer, Treasurer & Sec.

Ms. Elizabeth Donnelly
Director of Admin.

Mr. Edmund Cheung
VP of HR

Dr. Nadia Agopyan Ph.D.
Sr. VP of Regulatory Affairs

Dr. Robert Z. Florkiewicz Sr.
Sr. Director of Molecular Biology & Virology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRKR Stock - Frequently Asked Questions

Should I buy or sell Marker Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRKR, but not buy additional shares or sell existing shares.
View MRKR analyst ratings or view top-rated stocks.
What is Marker Therapeutics' stock price forecast for 2023?: 1 equities research analysts have issued 1-year target prices for Marker Therapeutics' shares. Their MRKR share price forecasts range from $1.00 to $1.50. On average, they expect the company's share price to reach $1.25 in the next twelve months. This suggests a possible upside of 316.5% from the stock's current price.
View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts.
How have MRKR shares performed in 2022?: Marker Therapeutics' stock was trading at $0.95 at the start of the year. Since then, MRKR stock has decreased by 68.4% and is now trading at $0.3001.
View the best growth stocks for 2022 here.
When is Marker Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our MRKR earnings forecast.
How were Marker Therapeutics' earnings last quarter?: Marker Therapeutics, Inc. (NASDAQ:MRKR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative net margin of 515.88% and a negative trailing twelve-month return on equity of 110.00%.

What other stocks do shareholders of Marker Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).
What is Marker Therapeutics' stock symbol?: Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."
Who are Marker Therapeutics' major shareholders?: Marker Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.11%), Long Focus Capital Management LLC (1.75%), Matrix Asset Advisors Inc. NY (0.48%), Renaissance Technologies LLC (0.18%) and Raymond James & Associates (0.11%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends.
How do I buy shares of Marker Therapeutics?: Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Marker Therapeutics' stock price today?: One share of MRKR stock can currently be purchased for approximately $0.30.
How much money does Marker Therapeutics make?: Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $25.09 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.
How can I contact Marker Therapeutics?: Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.

This page (NASDAQ:MRKR) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Marker Therapeutics - MRKR Stock Forecast, Price & News

Marker Therapeutics MarketRank™ Forecast

Overall MarketRank™